Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Dhanya K. Nambiar(Stanford Medicine), Quynh‐Thu Le(Stanford Medicine)

Journal of Clinical Investigation

November 10, 2019

10.1172/jci129025

Cited by 174

Related Papers

Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03

|Journal of Clinical Oncology|2009|87

Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1

|Oncotarget|2014|62

<i>NFE2L2</i> Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells

|Cancer Research|2023|56

Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment

|Cancer Research|2023|41

Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors

|Nature Biotechnology|2024|28